Publication
Congenital Glucagon-like Peptide-1 Deficiency in the Pathogenesis of Protracted Diarrhea in Mitchell–Riley Syndrome
dc.contributor.author | Nóbrega, S | |
dc.contributor.author | Monteiro, MP | |
dc.contributor.author | Pereira-da-Silva, L | |
dc.contributor.author | Pereira, SS | |
dc.contributor.author | Hartmann, B | |
dc.contributor.author | Holst, JJ | |
dc.contributor.author | Barbosa Silva, R | |
dc.contributor.author | Cordeiro-Ferreira, G | |
dc.date.accessioned | 2023-11-03T11:51:22Z | |
dc.date.available | 2023-11-03T11:51:22Z | |
dc.date.issued | 2021 | |
dc.description.abstract | Context: Mitchell-Riley syndrome due to RFX6 gene mutations is characterized by neonatal diabetes and protracted diarrhea. The RFX6 gene encodes a transcription factor involved in enteroendocrine cell differentiation required for beta-cell maturation. In contrast to the pathway by which RFX6 mutations leads to diabetes, the mechanisms underlying protracted diarrhea are unknown. Objective: To assess whether glucagon-like peptide-1 (GLP-1) was involved in the pathogenesis of Mitchell-Riley syndrome protracted diarrhea. Methods: Two case report descriptions. in a tertiary pediatric hospital. "Off-label" treatment with liraglutide. We describe 2 children diagnosed with Mitchell-Riley syndrome, presenting neonatal diabetes and protracted diarrhea. Both patients had nearly undetectable GLP-1 plasma levels and absence of GLP-1 immunostaining in distal intestine and rectum. The main outcome was to evaluate whether GLP-1 analogue therapy could improve Mitchell-Riley syndrome protracted diarrhea. Results: "Off-label" liraglutide treatment, licensed for type 2 diabetes treatment in children, was started as rescue therapy for protracted intractable diarrhea resulting in rapid improvement during the course of 12 months. Conclusion: Congenital GLP-1 deficiency was identified in patients with Mitchell-Riley syndrome. The favorable response to liraglutide further supports GLP-1 involvement in the pathogenesis of protracted diarrhea and its potential therapeutic use. | pt_PT |
dc.description.version | info:eu-repo/semantics/publishedVersion | pt_PT |
dc.identifier.citation | J Clin Endocrinol Metab . 2021 Mar 25;106(4):1084-1090 | pt_PT |
dc.identifier.doi | 10.1210/clinem/dgaa916 | pt_PT |
dc.identifier.uri | http://hdl.handle.net/10400.17/4733 | |
dc.language.iso | eng | pt_PT |
dc.peerreviewed | yes | pt_PT |
dc.publisher | Oxford University Press | pt_PT |
dc.subject | Child | pt_PT |
dc.subject | Consanguinity | pt_PT |
dc.subject | Diabetes Mellitus / blood | pt_PT |
dc.subject | Diabetes Mellitus / congenital | pt_PT |
dc.subject | Diabetes Mellitus / etiology* | pt_PT |
dc.subject | Diabetes Mellitus / genetics | pt_PT |
dc.subject | Diarrhea / blood | pt_PT |
dc.subject | Diarrhea / congenital | pt_PT |
dc.subject | Diarrhea / etiology* | pt_PT |
dc.subject | Fatal Outcome | pt_PT |
dc.subject | Gallbladder Diseases / blood | pt_PT |
dc.subject | Gallbladder Diseases / congenital | pt_PT |
dc.subject | Gallbladder Diseases / etiology* | pt_PT |
dc.subject | Glucagon-Like Peptide 1 / blood | pt_PT |
dc.subject | Glucagon-Like Peptide 1 / deficiency* | pt_PT |
dc.subject | Glucagon-Like Peptide 1 / physiology | pt_PT |
dc.subject | Glucagon-Like Peptide 1 / physiology | pt_PT |
dc.subject | Hepatic Encephalopathy / pathology | pt_PT |
dc.subject | Infant | pt_PT |
dc.subject | Intestinal Atresia / blood | pt_PT |
dc.subject | Intestinal Atresia / etiology* | pt_PT |
dc.subject | Mutation, Missense | pt_PT |
dc.subject | Portugal | pt_PT |
dc.subject | Regulatory Factor X Transcription Factors / genetics | pt_PT |
dc.subject | HDE GAS PED | pt_PT |
dc.subject | HDE UCI NEO | pt_PT |
dc.title | Congenital Glucagon-like Peptide-1 Deficiency in the Pathogenesis of Protracted Diarrhea in Mitchell–Riley Syndrome | pt_PT |
dc.type | journal article | |
dspace.entity.type | Publication | |
oaire.citation.endPage | e1090 | pt_PT |
oaire.citation.issue | 4 | pt_PT |
oaire.citation.startPage | e1084 | pt_PT |
oaire.citation.title | The Journal of Clinical Endocrinology & Metabolism | pt_PT |
oaire.citation.volume | 106 | pt_PT |
rcaap.rights | openAccess | pt_PT |
rcaap.type | article | pt_PT |